Blog

RSS Feed
Posted by Michael Wonder on 27 Jun 2025

Xtandi (enzalutamide) now funded in Ontario for all approved prostate cancer indications

26 June 2025 - Today, Astellas Pharma Canada announced that Xtandi (enzalutamide) is now funded by the Ontario Drug Benefit Program ...

Read more →
Posted by Michael Wonder on 02 Jun 2025

Enhertu (trastuzumab deruxtecan) receives time limited reimbursement recommendation from Canada's Drug Agency for gastric cancer

23 May 2025 - AstraZeneca and Daiichi Sankyo are pleased to announce that Canada's Drug Agency has issued a time-limited reimbursement ...

Read more →
Posted by Michael Wonder on 18 Apr 2023

AbbVie announces provincial reimbursement for Vraylar (cariprazine) for the treatment of schizophrenia in Québec

17 April 2023 - AbbVie today announced that Vraylat is now listed as an exception medication status on the list of ...

Read more →